What is it about?
HIVs are tough to combat because their enzymes, which are the primary drug targets, have flexible residues. Designing effective drugs in such cases requires detailed understanding of the residues involved and the degree of their flexibility. This forms the basis of this article.
Featured Image
Read the Original
This page is a summary of: Flexibility of Important HIV-1 Targets and in silico Design of anti- HIV Drugs, July 2018, Bentham Science Publishers,
DOI: 10.2174/2212796811666170807154035.
You can read the full text:
Contributors
The following have contributed to this page
